<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
            xmlns="http://www.w3.org/1999/xhtml"
            xmlns:arr="http://xbrl.dcca.dk/arr"
            xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12"
            xmlns:cmn="http://xbrl.dcca.dk/cmn"
            xmlns:sob="http://xbrl.dcca.dk/sob"
            xmlns:link="http://www.xbrl.org/2003/linkbase"
            xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
            xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
            xmlns:mrv="http://xbrl.dcca.dk/mrv"
            xmlns:fsa="http://xbrl.dcca.dk/fsa"
            xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
            xmlns:gsd="http://xbrl.dcca.dk/gsd"
            xmlns:xlink="http://www.w3.org/1999/xlink"
            xml:lang="en">
   <link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"
                   xlink:type="simple"/>
   <xbrli:context id="ctx-1">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-21">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-22">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-23">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-24">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
            <cmn:auditorIdentifier>1</cmn:auditorIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-4">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2021-01-01</xbrli:startDate>
         <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-6">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2020-01-01</xbrli:startDate>
         <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-8">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2019-01-01</xbrli:startDate>
         <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-10">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2018-01-01</xbrli:startDate>
         <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-3">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-5">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-7">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-9">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-11">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-12">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-15">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-18">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-13">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-16">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-19">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-14">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-17">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-20">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-2">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2022-01-01</xbrli:startDate>
         <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
            <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:unit id="dkk">
      <xbrli:measure>iso4217:DKK</xbrli:measure>
   </xbrli:unit>
   <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
   </xbrli:unit>
   <gsd:DateOfGeneralMeeting contextRef="ctx-1">2023-06-19</gsd:DateOfGeneralMeeting>
   <gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx-1" id="pp-value-1-1" xml:lang="en">Ana Isabel Infante Gonzalez De La Aleja </gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
   <sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx-1" id="pp-value-3-1" xml:lang="en">The Board of Directors and Executive Board have today discussed and approved the Annual Report of UCB NORDIC A/S for the financial year 1 January - 31 December 2022.The annual report is prepared in accordance with the Danish Financial Statements Act.In our opinion the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31  December 2022 and  of  the results of the  company's operations for the  financial year 1 January - 31 December 2022.Further, in our opinion, the Management's review gives a fair review of the development in the Company’s operations and financial matters, of the results for the year and of the Company’s financial position.We recommend that the Annual Report be approved at the Annual General Meeting.</sob:StatementByExecutiveAndSupervisoryBoards>
   <sob:PlaceOfSignatureOfStatement contextRef="ctx-1" xml:lang="en">Copenhagen</sob:PlaceOfSignatureOfStatement>
   <sob:DateOfApprovalOfAnnualReport contextRef="ctx-1">2023-06-19</sob:DateOfApprovalOfAnnualReport>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-21" id="pp-value-6-1" xml:lang="en">Ana Isabel Infante GonzalezDe La Aleja </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-21" xml:lang="en">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-22" xml:lang="en">Per Ove Jonas Berg</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-23" xml:lang="en">Afshin Risseh</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">To the shareholder of UCB NORDIC A/S</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
   <arr:OpinionOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-11-1" xml:lang="en">In our opinion, the Financial Statements give a true and fair view of the Company’s assets, liabilities and financial position of the Company at 31 December 2022, and of the results of the Company’s operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.We  have  audited  the  Financial  Statements  of  UCB  NORDIC  A/S  for  the  financial  year  1  January  - 31  December  2022,  which  comprise  income  statement,  balance  sheet,  statement  of  changes  in  equity and notes, including a summary of significant accounting policies.</arr:OpinionOnAuditedFinancialStatements>
   <arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx-1" id="pp-value-12-1" xml:lang="en">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements  applicable  in  Denmark.  Our  responsibilities  under  those  standards  and  requirements  are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for  Accountants’  Code  of  Ethics  for  Professional  Accountants  (IESBA  Code)  and  the  additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with  these  requirements.  We  believe  that  the  audit  evidence  we  have  obtained  is  sufficient  and appropriate to provide a basis for our opinion.</arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
   <arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-13-1" xml:lang="en">Management is responsible for Management’s Review.Our opinion on  the financial  statements  does not  cover  Management’s Review,  and we  do  not express any form of assurance conclusion thereon.In  connection  with  our  audit  of  the  financial  statements,  our  responsibility  is  to  read  Management’s Review  and,  in  doing  so,  consider  whether  Management’s  Review  is  materially  inconsistent  with  the financial  statements  or  our  knowledge  obtained  during  the  audit,  or  otherwise  appears  to  be  materially misstated.Moreover,  it  is  our  responsibility  to  consider  whether  Management’s  Review  provides  the  information required under the Danish Financial Statements Act.Based  on  the  work  we  have  performed,  in  our  view,  Management’s  Review  is  in  accordance  with  the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management’s Review.</arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
   <arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx-1" id="pp-value-14-1" xml:lang="en">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance  with  the  Danish  Financial  Statements  Act,  and  for  such  internal  control  as  Management determines  is  necessary  to  enable  the  preparation  of  financial  statements  that  are  free  from  material misstatement, whether due to fraud or error.In preparing the financial statements, Management is responsible for assessing the Company’s ability to continue as  a  going  concern,  disclosing, as  applicable,  matters  related  to going  concern  and  using  the going  concern  basis  of  accounting  in  preparing  the  financial  statements  unless  Management  either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
   <arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx-1" id="pp-value-15-1" xml:lang="en">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free  from  material  misstatement,  whether  due  to  fraud  or  error,  and  to  issue  an  auditor’s  report  that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit  conducted  in  accordance  with  ISAs  and  the  additional  requirements  applicable  in  Denmark  will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.As  part  of  an  audit  conducted  in  accordance  with  ISAs  and  the  additional  requirements  applicable  in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:– Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is  sufficient  and  appropriate  to  provide  a  basis  for  our  opinion.  The  risk  of  not  detecting  a  material misstatement  resulting  from  fraud  is  higher  than  for  one  resulting  from  error  as  fraud  may  involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.– Obtain an understanding  of internal control  relevant to  the  audit in  order  to design  audit procedures that  are  appropriate  in  the  circumstances,  but  not  for  the  purpose  of  expressing  an  opinion  on  the effectiveness of the Company’s internal control.– Evaluate  the  appropriateness  of  accounting  policies  used  and  the  reasonableness  of  accounting estimates and related disclosures made by Management.– Conclude on  the  appropriateness of  Management’s use  of the  going concern  basis  of accounting  in pre-paring  the  financial  statements  and,  based  on  the  audit  evidence  obtained,  whether  a  material uncertainty  exists  related  to  events  or  conditions  that  may  cast  significant  doubt  on  the  Company’s ability  to  continue  as  a  going  concern.  If  we  conclude  that  a  material  uncertainty  exists,  we  are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence  obtained  up  to  the  date  of  our  auditor’s  report.  However,  future  events  or  conditions  may cause the Company to cease to continue as a going concern.– Evaluate  the  overall  presentation,  structure  and  contents  of  the  financial  statements,  including  the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.We  communicate  with  those  charged  with  governance  regarding,  among  other  matters,  the  planned scope  and  timing  of  the  audit  and  significant  audit  findings,  including  any  significant  deficiencies  in internal control that we identify during our audit.</arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
   <arr:SignatureOfAuditorsPlace contextRef="ctx-1" xml:lang="en">København Ø</arr:SignatureOfAuditorsPlace>
   <arr:SignatureOfAuditorsDate contextRef="ctx-1">2023-06-19</arr:SignatureOfAuditorsDate>
   <cmn:NameOfAuditFirm contextRef="ctx-24" id="pp-value-22-1" xml:lang="en">MazarsStatsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
   <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-24" xml:lang="en">31061741</cmn:IdentificationNumberCvrOfAuditFirm>
   <cmn:NameAndSurnameOfAuditor contextRef="ctx-24" id="pp-value-19-1" xml:lang="en">Karsten Vedel</cmn:NameAndSurnameOfAuditor>
   <cmn:DescriptionOfAuditor contextRef="ctx-24" id="pp-value-20-1" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
   <cmn:IdentificationNumberOfAuditor contextRef="ctx-24" xml:lang="en">mne47841</cmn:IdentificationNumberOfAuditor>
   <gsd:NameOfReportingEntity contextRef="ctx-1" id="pp-value-27-1" xml:lang="en">UCB NORDIC A/S</gsd:NameOfReportingEntity>
   <gsd:AddressOfReportingEntityStreetName contextRef="ctx-1" id="pp-value-28-1" xml:lang="en">Edvard Thomsens Vej</gsd:AddressOfReportingEntityStreetName>
   <gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx-1" xml:lang="en">14, 7.</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
   <gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" xml:lang="en">2300</gsd:AddressOfReportingEntityPostCodeIdentifier>
   <gsd:AddressOfReportingEntityDistrictName contextRef="ctx-1" xml:lang="en">København S</gsd:AddressOfReportingEntityDistrictName>
   <gsd:TelephoneNumberOfReportingEntity contextRef="ctx-1" xml:lang="en">32462400</gsd:TelephoneNumberOfReportingEntity>
   <gsd:FaxNumberOfReportingEntity contextRef="ctx-1" xml:lang="en">32462401</gsd:FaxNumberOfReportingEntity>
   <gsd:HomepageOfReportingEntity contextRef="ctx-1" id="pp-value-34-1" xml:lang="en">www.ucb.com</gsd:HomepageOfReportingEntity>
   <gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1" id="pp-value-35-1" xml:lang="en">26688949</gsd:IdentificationNumberCvrOfReportingEntity>
   <gsd:DateOfFoundationOfReportingEntity contextRef="ctx-1">2002-07-05</gsd:DateOfFoundationOfReportingEntity>
   <gsd:RegisteredOfficeOfReportingEntity contextRef="ctx-1" xml:lang="en">Copenhagen</gsd:RegisteredOfficeOfReportingEntity>
   <gsd:AddressOfAuditorStreetName contextRef="ctx-24" xml:lang="en">Midtermolen</gsd:AddressOfAuditorStreetName>
   <gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx-24" id="pp-value-24-1" xml:lang="en">1, 2. tv.</gsd:AddressOfAuditorStreetBuildingIdentifier>
   <gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx-24" xml:lang="en">2100</gsd:AddressOfAuditorPostCodeIdentifier>
   <gsd:AddressOfAuditorDistrictName contextRef="ctx-24" xml:lang="en">København Ø</gsd:AddressOfAuditorDistrictName>
   <fsa:GrossResult contextRef="ctx-1" decimals="-3" unitRef="dkk">61499000</fsa:GrossResult>
   <fsa:GrossResult contextRef="ctx-4" decimals="-3" unitRef="dkk">60527000</fsa:GrossResult>
   <fsa:GrossResult contextRef="ctx-6" decimals="-3" unitRef="dkk">46217000</fsa:GrossResult>
   <fsa:GrossResult contextRef="ctx-8" decimals="-3" unitRef="dkk">39541000</fsa:GrossResult>
   <fsa:GrossResult contextRef="ctx-10" decimals="-3" unitRef="dkk">34615000</fsa:GrossResult>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-1" decimals="-3" unitRef="dkk">5333000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-4" decimals="-3" unitRef="dkk">4032000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-6" decimals="-3" unitRef="dkk">4948000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-8" decimals="-3" unitRef="dkk">4514000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-10" decimals="-3" unitRef="dkk">4560000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-1" decimals="-3" unitRef="dkk">5128000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-4" decimals="-3" unitRef="dkk">3817000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-6" decimals="-3" unitRef="dkk">4650000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-8" decimals="-3" unitRef="dkk">4246000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-10" decimals="-3" unitRef="dkk">4403000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:ProfitLoss contextRef="ctx-1" decimals="-3" unitRef="dkk">4004000</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-4" decimals="-3" unitRef="dkk">3016000</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-6" decimals="-3" unitRef="dkk">3721000</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-8" decimals="-3" unitRef="dkk">3591000</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-10" decimals="-3" unitRef="dkk">3268000</fsa:ProfitLoss>
   <fsa:Assets contextRef="ctx-3" decimals="-3" unitRef="dkk">57654000</fsa:Assets>
   <fsa:Assets contextRef="ctx-5" decimals="-3" unitRef="dkk">59202000</fsa:Assets>
   <fsa:Assets contextRef="ctx-7" decimals="-3" unitRef="dkk">60523000</fsa:Assets>
   <fsa:Assets contextRef="ctx-9" decimals="-3" unitRef="dkk">58816000</fsa:Assets>
   <fsa:Assets contextRef="ctx-11" decimals="-3" unitRef="dkk">68871000</fsa:Assets>
   <fsa:Equity contextRef="ctx-3" decimals="-3" unitRef="dkk">15118000</fsa:Equity>
   <fsa:Equity contextRef="ctx-5" decimals="-3" unitRef="dkk">14114000</fsa:Equity>
   <fsa:Equity contextRef="ctx-7" decimals="-3" unitRef="dkk">11094000</fsa:Equity>
   <fsa:Equity contextRef="ctx-9" decimals="-3" unitRef="dkk">10573000</fsa:Equity>
   <fsa:Equity contextRef="ctx-11" decimals="-3" unitRef="dkk">10282000</fsa:Equity>
   <fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx-1" decimals="-3" unitRef="dkk">0</fsa:InvestmentInPropertyPlantAndEquipment>
   <fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx-4" decimals="-3" unitRef="dkk">0</fsa:InvestmentInPropertyPlantAndEquipment>
   <fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx-6" decimals="-3" unitRef="dkk">0</fsa:InvestmentInPropertyPlantAndEquipment>
   <fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx-8" decimals="-3" unitRef="dkk">0</fsa:InvestmentInPropertyPlantAndEquipment>
   <fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx-10" decimals="-3" unitRef="dkk">0</fsa:InvestmentInPropertyPlantAndEquipment>
   <mrv:ReturnOnEquity contextRef="ctx-1" decimals="2" unitRef="pure">0.27</mrv:ReturnOnEquity>
   <mrv:ReturnOnEquity contextRef="ctx-4" decimals="2" unitRef="pure">0.24</mrv:ReturnOnEquity>
   <mrv:ReturnOnEquity contextRef="ctx-6" decimals="2" unitRef="pure">0.34</mrv:ReturnOnEquity>
   <mrv:ReturnOnEquity contextRef="ctx-8" decimals="2" unitRef="pure">0.34</mrv:ReturnOnEquity>
   <mrv:ReturnOnEquity contextRef="ctx-10" decimals="2" unitRef="pure">0.32</mrv:ReturnOnEquity>
   <mrv:SolvencyRatio contextRef="ctx-1" decimals="2" unitRef="pure">0.26</mrv:SolvencyRatio>
   <mrv:SolvencyRatio contextRef="ctx-4" decimals="2" unitRef="pure">0.24</mrv:SolvencyRatio>
   <mrv:SolvencyRatio contextRef="ctx-6" decimals="2" unitRef="pure">0.18</mrv:SolvencyRatio>
   <mrv:SolvencyRatio contextRef="ctx-8" decimals="2" unitRef="pure">0.18</mrv:SolvencyRatio>
   <mrv:SolvencyRatio contextRef="ctx-10" decimals="2" unitRef="pure">0.15</mrv:SolvencyRatio>
   <mrv:InformationOnCalculationOfKeyFiguresAndFinancialRatios contextRef="ctx-1" id="pp-value-38-1" xml:lang="en">The financial ratios have been calculated as follows:Return on equity Profit/loss for the year x 100Average equitySolvency ratio Equity at year end x 100Total assets at year end</mrv:InformationOnCalculationOfKeyFiguresAndFinancialRatios>
   <mrv:ManagementsReview contextRef="ctx-1" id="pp-value-39-1" xml:lang="en">Operating reviewPrincipal activity The objective of the Company is to carry out business activity in the fields of biotechnology, medicine and chemistry and related areas as defined by the board.Uncertainty regarding recognition and measurementThe  valuation  of  assets  and  liabilities  is  made  in  accordance  with  current  accounting  policies,  and Management  of  the  Company  is  of  the  opinion  that  no  uncertainty  is  related  to  recognition  and measurement.Unusual circumstancesThere have been no unusual circumstances affecting recognition and measurement in the financial year 2022.Profit/loss for the year (including comparison with forecasts previously announced)Our portfolio in Denmark is comprised of our biologic  brands for Immunology diseases Cimzia, Bimzelx and  within  the  Bone  Builder  environment  Evenity.  The  Epilepsy  portfolio  is  comprised  of  the  drugs Briviact, Vimpat, Keppra and Fintepla, a recently launched product for treatment of seizures associated with Dravet  syndrome  (DS)  and  Lennox-Gastaut syndrome. Next to Epilepsy products we have Neupro helping people with Parkinson disease. As part of established brands we commercialize Zyrtec, Xyzal as treatment for allergies and Xyrem used to treat adults who suffer from narcolepsy.  The Company's revenue increased by 44% in 2022 compared to previous year. Cimzia increased by 72% versus last year, driven by winning the tender. Last year a parallel trader won the tender on the PFS. In November 2022 we launched Bimzelx for people suffering from Psoriasis.Evenity had an exponential growth of 142% on its second full year of sales which triggered an increase of 1.2M€ Vs. last year sales.The Neurology portfolio continue performing consistently. New launch Fintepla lead the growth although total revenues are impacted from Parallel Import.In  Established  brands  the  revenues  decreased  by  39%  mostly  driven  by  Xyrem  with  stiff  generic competition. The profit for 2022 amounts to DKK 4,004 thousand versus DKK 3,016 thousand in 2021 which is in line with previous year.The financial year was well above the forecast due to a strong performance of the Immunology and Bone portfolio and new the launch of Fintepla.Particular risksRisk management (operating and financial risk)A  global  Risk  Management  policy,  applicable  for  the  whole  UCB  Group  and  its  affiliates  worldwide, describes  the  UCB  Group's  commitment  to  provide  an  effective  risk  management  system  across  the company  in  order  to  minimize  its  exposure  to  risks  that  could  threaten  the  UCB  Group's  corporate objectives.The Board of Directors is responsible for approving the UCB Group's strategy, goals and objectives and overseeing the establishment, implementation and review of the Group's risk management system.Operating reviewThe  Board  is  assisted  by  the  Audit  Committee  in  its  responsibility  for  the  appreciation  of  risk management. The Audit Committee examines on a regular basis the areas where risks could significantly affect the  financial  situation  or  reputation of  the UCB  Group. The Audit  Committee  monitors  the overall risk management process of UCB.The main risks faced by the Company relate to financial risks in particular pricing and foreign exchange risk.The Company's performance is impacted by parallel trade.Other  insurable  risks  are  insured  by  the  Company  to  the  extent  that  the  directors  consider  appropriate having due regard to the considered impact from said risk.Environmental mattersThe Company's activities do not have any material environmental impact.Research and development activitiesThe Company had some local clinical trial activities in 2022.OutlookIn 2022  no  special  events  or exceptional  items of  income and  expense from  the normal  activities  have taken place,which have influenced or could influence the future expectations for UCB NORDIC A/S. Therefore, we expect no changes in the financing environment as well. We expect a result before tax for 2023 of approximately the same amount as in 2022.</mrv:ManagementsReview>
   <fsa:GrossResult contextRef="ctx-1" decimals="-3" unitRef="dkk">61499000</fsa:GrossResult>
   <fsa:GrossResult contextRef="ctx-4" decimals="-3" unitRef="dkk">60527000</fsa:GrossResult>
   <fsa:EmployeeBenefitsExpense contextRef="ctx-1" decimals="-3" unitRef="dkk">56120000</fsa:EmployeeBenefitsExpense>
   <fsa:EmployeeBenefitsExpense contextRef="ctx-4" decimals="-3" unitRef="dkk">56434000</fsa:EmployeeBenefitsExpense>
   <fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx-1" decimals="-3" unitRef="dkk">46000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
   <fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx-4" decimals="-3" unitRef="dkk">61000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-1" decimals="-3" unitRef="dkk">5333000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-4" decimals="-3" unitRef="dkk">4032000</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:OtherFinanceIncome contextRef="ctx-1" decimals="-3" unitRef="dkk">113000</fsa:OtherFinanceIncome>
   <fsa:OtherFinanceIncome contextRef="ctx-4" decimals="-3" unitRef="dkk">69000</fsa:OtherFinanceIncome>
   <fsa:OtherFinanceExpenses contextRef="ctx-1" decimals="-3" unitRef="dkk">318000</fsa:OtherFinanceExpenses>
   <fsa:OtherFinanceExpenses contextRef="ctx-4" decimals="-3" unitRef="dkk">284000</fsa:OtherFinanceExpenses>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-1" decimals="-3" unitRef="dkk">5128000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-4" decimals="-3" unitRef="dkk">3817000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:TaxExpense contextRef="ctx-1" decimals="-3" unitRef="dkk">1124000</fsa:TaxExpense>
   <fsa:TaxExpense contextRef="ctx-4" decimals="-3" unitRef="dkk">802000</fsa:TaxExpense>
   <fsa:ProfitLoss contextRef="ctx-1" decimals="-3" unitRef="dkk">4004000</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-4" decimals="-3" unitRef="dkk">3016000</fsa:ProfitLoss>
   <fsa:FixturesFittingsToolsAndEquipment contextRef="ctx-3" decimals="-3" unitRef="dkk">3000</fsa:FixturesFittingsToolsAndEquipment>
   <fsa:FixturesFittingsToolsAndEquipment contextRef="ctx-5" decimals="-3" unitRef="dkk">49000</fsa:FixturesFittingsToolsAndEquipment>
   <fsa:OtherLongtermReceivables contextRef="ctx-3" decimals="-3" unitRef="dkk">528000</fsa:OtherLongtermReceivables>
   <fsa:OtherLongtermReceivables contextRef="ctx-5" decimals="-3" unitRef="dkk">463000</fsa:OtherLongtermReceivables>
   <fsa:NoncurrentAssets contextRef="ctx-3" decimals="-3" unitRef="dkk">531000</fsa:NoncurrentAssets>
   <fsa:NoncurrentAssets contextRef="ctx-5" decimals="-3" unitRef="dkk">512000</fsa:NoncurrentAssets>
   <fsa:ManufacturedGoodsAndGoodsForResale contextRef="ctx-3" decimals="-3" unitRef="dkk">7695000</fsa:ManufacturedGoodsAndGoodsForResale>
   <fsa:ManufacturedGoodsAndGoodsForResale contextRef="ctx-5" decimals="-3" unitRef="dkk">16343000</fsa:ManufacturedGoodsAndGoodsForResale>
   <fsa:ShorttermTradeReceivables contextRef="ctx-3" decimals="-3" unitRef="dkk">17581000</fsa:ShorttermTradeReceivables>
   <fsa:ShorttermTradeReceivables contextRef="ctx-5" decimals="-3" unitRef="dkk">10887000</fsa:ShorttermTradeReceivables>
   <fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx-3" decimals="-3" unitRef="dkk">19796000</fsa:ShorttermReceivablesFromGroupEnterprises>
   <fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx-5" decimals="-3" unitRef="dkk">19693000</fsa:ShorttermReceivablesFromGroupEnterprises>
   <fsa:DeferredIncomeAssets contextRef="ctx-3" decimals="-3" unitRef="dkk">169000</fsa:DeferredIncomeAssets>
   <fsa:DeferredIncomeAssets contextRef="ctx-5" decimals="-3" unitRef="dkk">169000</fsa:DeferredIncomeAssets>
   <fsa:CurrentDeferredTaxAssets contextRef="ctx-3" decimals="-3" unitRef="dkk">1100000</fsa:CurrentDeferredTaxAssets>
   <fsa:CurrentDeferredTaxAssets contextRef="ctx-5" decimals="-3" unitRef="dkk">1286000</fsa:CurrentDeferredTaxAssets>
   <fsa:ShorttermReceivables contextRef="ctx-3" decimals="-3" unitRef="dkk">38646000</fsa:ShorttermReceivables>
   <fsa:ShorttermReceivables contextRef="ctx-5" decimals="-3" unitRef="dkk">32035000</fsa:ShorttermReceivables>
   <fsa:CashAndCashEquivalents contextRef="ctx-3" decimals="-3" unitRef="dkk">10782000</fsa:CashAndCashEquivalents>
   <fsa:CashAndCashEquivalents contextRef="ctx-5" decimals="-3" unitRef="dkk">10312000</fsa:CashAndCashEquivalents>
   <fsa:CurrentAssets contextRef="ctx-3" decimals="-3" unitRef="dkk">57123000</fsa:CurrentAssets>
   <fsa:CurrentAssets contextRef="ctx-5" decimals="-3" unitRef="dkk">58690000</fsa:CurrentAssets>
   <fsa:Assets contextRef="ctx-3" decimals="-3" unitRef="dkk">57654000</fsa:Assets>
   <fsa:Assets contextRef="ctx-5" decimals="-3" unitRef="dkk">59202000</fsa:Assets>
   <fsa:ContributedCapital contextRef="ctx-3" decimals="-3" unitRef="dkk">850000</fsa:ContributedCapital>
   <fsa:ContributedCapital contextRef="ctx-5" decimals="-3" unitRef="dkk">850000</fsa:ContributedCapital>
   <fsa:RetainedEarnings contextRef="ctx-3" decimals="-3" unitRef="dkk">11368000</fsa:RetainedEarnings>
   <fsa:RetainedEarnings contextRef="ctx-5" decimals="-3" unitRef="dkk">10264000</fsa:RetainedEarnings>
   <fsa:ProposedDividendRecognisedInEquity contextRef="ctx-3" decimals="-3" unitRef="dkk">2900000</fsa:ProposedDividendRecognisedInEquity>
   <fsa:ProposedDividendRecognisedInEquity contextRef="ctx-5" decimals="-3" unitRef="dkk">3000000</fsa:ProposedDividendRecognisedInEquity>
   <fsa:Equity contextRef="ctx-3" decimals="-3" unitRef="dkk">15118000</fsa:Equity>
   <fsa:Equity contextRef="ctx-5" decimals="-3" unitRef="dkk">14114000</fsa:Equity>
   <fsa:OtherProvisions contextRef="ctx-3" decimals="-3" unitRef="dkk">4530000</fsa:OtherProvisions>
   <fsa:OtherProvisions contextRef="ctx-5" decimals="-3" unitRef="dkk">5461000</fsa:OtherProvisions>
   <fsa:Provisions contextRef="ctx-3" decimals="-3" unitRef="dkk">4530000</fsa:Provisions>
   <fsa:Provisions contextRef="ctx-5" decimals="-3" unitRef="dkk">5461000</fsa:Provisions>
   <fsa:ShorttermTradePayables contextRef="ctx-3" decimals="-3" unitRef="dkk">3835000</fsa:ShorttermTradePayables>
   <fsa:ShorttermTradePayables contextRef="ctx-5" decimals="-3" unitRef="dkk">4357000</fsa:ShorttermTradePayables>
   <fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx-3" decimals="-3" unitRef="dkk">23317000</fsa:ShorttermPayablesToGroupEnterprises>
   <fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx-5" decimals="-3" unitRef="dkk">24677000</fsa:ShorttermPayablesToGroupEnterprises>
   <fsa:ShorttermTaxPayables contextRef="ctx-3" decimals="-3" unitRef="dkk">512000</fsa:ShorttermTaxPayables>
   <fsa:ShorttermTaxPayables contextRef="ctx-5" decimals="-3" unitRef="dkk">1350000</fsa:ShorttermTaxPayables>
   <fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx-3" decimals="-3" unitRef="dkk">10342000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
   <fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx-5" decimals="-3" unitRef="dkk">9243000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
   <fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx-3" decimals="-3" unitRef="dkk">38006000</fsa:ShorttermLiabilitiesOtherThanProvisions>
   <fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx-5" decimals="-3" unitRef="dkk">39627000</fsa:ShorttermLiabilitiesOtherThanProvisions>
   <fsa:LiabilitiesOtherThanProvisions contextRef="ctx-3" decimals="-3" unitRef="dkk">38006000</fsa:LiabilitiesOtherThanProvisions>
   <fsa:LiabilitiesOtherThanProvisions contextRef="ctx-5" decimals="-3" unitRef="dkk">39627000</fsa:LiabilitiesOtherThanProvisions>
   <fsa:LiabilitiesAndEquity contextRef="ctx-3" decimals="-3" unitRef="dkk">57654000</fsa:LiabilitiesAndEquity>
   <fsa:LiabilitiesAndEquity contextRef="ctx-5" decimals="-3" unitRef="dkk">59202000</fsa:LiabilitiesAndEquity>
   <fsa:Equity contextRef="ctx-12" decimals="-3" unitRef="dkk">850000</fsa:Equity>
   <fsa:Equity contextRef="ctx-15" decimals="-3" unitRef="dkk">10264000</fsa:Equity>
   <fsa:Equity contextRef="ctx-18" decimals="-3" unitRef="dkk">3000000</fsa:Equity>
   <fsa:Equity contextRef="ctx-5" decimals="-3" unitRef="dkk">14114000</fsa:Equity>
   <fsa:DistributedDividendsFromGroupEnterprises contextRef="ctx-13" decimals="-3" unitRef="dkk">0</fsa:DistributedDividendsFromGroupEnterprises>
   <fsa:DistributedDividendsFromGroupEnterprises contextRef="ctx-16" decimals="-3" unitRef="dkk">0</fsa:DistributedDividendsFromGroupEnterprises>
   <fsa:DistributedDividendsFromGroupEnterprises contextRef="ctx-19" decimals="-3" unitRef="dkk">-3000000</fsa:DistributedDividendsFromGroupEnterprises>
   <fsa:DistributedDividendsFromGroupEnterprises contextRef="ctx-1" decimals="-3" unitRef="dkk">-3000000</fsa:DistributedDividendsFromGroupEnterprises>
   <fsa:TransferredFromSharePremium contextRef="ctx-13" decimals="-3" unitRef="dkk">0</fsa:TransferredFromSharePremium>
   <fsa:TransferredFromSharePremium contextRef="ctx-16" decimals="-3" unitRef="dkk">1104000</fsa:TransferredFromSharePremium>
   <fsa:TransferredFromSharePremium contextRef="ctx-19" decimals="-3" unitRef="dkk">2900000</fsa:TransferredFromSharePremium>
   <fsa:TransferredFromSharePremium contextRef="ctx-1" decimals="-3" unitRef="dkk">4004000</fsa:TransferredFromSharePremium>
   <fsa:Equity contextRef="ctx-14" decimals="-3" unitRef="dkk">850000</fsa:Equity>
   <fsa:Equity contextRef="ctx-17" decimals="-3" unitRef="dkk">11368000</fsa:Equity>
   <fsa:Equity contextRef="ctx-20" decimals="-3" unitRef="dkk">2900000</fsa:Equity>
   <fsa:Equity contextRef="ctx-3" decimals="-3" unitRef="dkk">15118000</fsa:Equity>
   <fsa:DisclosureOfAccountingPolicies contextRef="ctx-1" id="pp-value-42-1" xml:lang="en">The annual report of UCB  NORDIC A/S  for  2022 has been prepared  in  accordance with the provisions applying to reporting class C entities with opt-in from higher accounting class under the Danish Financial Statements Act.Foreign currency translationOn initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at  the  transaction  date.  Foreign  exchange  differences  arising  between  the  exchange  rates  at  the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.Income statementGross ProfitWith reference to section §81 of the Danish Financial Statements Act, revenue has not been disclosed in the annual report.RevenueRevenue  from  the  sale  of  goods  for  resale  and  finished  goods  is  recognised  in  the  income  statement when delivery and transfer of risk to the buyer has been made before year end.Revenue is recognised excluding VAT and net of discounts relating to sales.Cost of salesCost of sales comprises costs incurred to generate revenue for the year. This item also comprises direct costs for goods for resale and changes to inventory of goods for resale.Other external costsOther  external  costs  comprise  distribution  costs  and  costs  related  to  sales,  sales  campaigns, administration, office premises, operating leases, etc.Staff costsStaff costs comprise wages and salaries, including holiday allowance, pension and other social security costs, etc., to the Company's employees, excluding reimbursements from public authorities.Financial income and expensesFinancial income and expenses comprise interest, realised and unrealised exchange adjustments as well as extra payments and refunds under the on-account taxation scheme.Tax on profit for the yearTax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit  for  the  year  is  recognised  in  the  income  statement,  whereas  the  tax attributable  to the  equity transactions is recognised directly in equity.Balance sheetProperty, plant and equipmentLeasehold  improvements  and  equipment  are  measured  at  cost  less  accumulated  depreciation  and impairment losses.Cost comprises the purchase price and any costs directly attributable to the acquisition until the date on which  the  asset  is  available  for  use.  Indirect  production  overheads  and  borrowing  costs  are  not recognised in cost.Where individual components of an item of property, plant and equipment have different useful lives, they are accounted for as separate items, which are depreciated separately.The useful life and residual value are reassessed annually. Changes are treated as accounting estimates, and the effect on depreciation is recognised prospectively. The expected useful lives of the assets are as follows:Leasehold improvements and equipment 5 yearsGains and losses on the disposal of property, plant and equipment are stated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses are recognised in the income statement as other operating income or other operating costs, respectively.Impairment of property, plant and equipmentThe  carrying  amount  of  property,  plant  and  equipment  as  well  as  investments  in  group  enterprises  is subject  to  an  annual  test  for  indications  of  impairment  other  than  the  decrease  in  value  reflected  by depreciation or amortisation.Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may  be impaired.  Write-down is  made  to the  recoverable amount  if this  is lower  than  the  carrying amount.InventoriesInventories are measured at the lower of cost under the FIFO method and net realisable value.ReceivablesReceivables are measured at amortised cost.Write-down  is  made  for  bad  debt  losses  where  there  is  an  objective  indication  that  a  receivable  or  a portfolio of receivables has been impaired. If there is an objective indication that an individual receivable has been impaired, write-down is made on an individual basis.Receivables with no objective indication of individual impairment are assessed for objective indication of impairment on a portfolio basis. The portfolios are primarily based on the debtors' registered offices and credit  rating  in  accordance  with  the  Company's  credit  risk  management  policy. The  objective  indicators used in relation to portfolios are determined on the basis of historical loss experience.Write-downs are calculated as the difference between the carrying amount of receivables and the present value  of  forecast  cash  flows,  including  the  realisable  value  of  any  collateral  received.  The  effective interest rate for the individual receivable or portfolio is used as discount rate.Other receivables consists of guarantee paid to third party.PrepaymentsPrepayments comprise prepaid expenses concerning subsequent financial years.Deferred tax assets and liabilitiesDeferred tax is recognised in respect of all temporary differences between the carrying amount and the tax base of assets and liabilities.Deferred  tax  is  measured  on  the  basis  of  the  tax  rules  and  tax  rates  that  will  be  effective  under  the legislation at  the  balance  sheet  date  when  the  deferred  tax  is  expected to  crystallise  as  current  tax.  In cases where the computation of the tax base may be made according to alternative tax rules, deferred tax is measured on the basis of the intended use of the asset and settlement of the liability, respectively.Deferred tax assets are  measured  at the value at  which  the asset is expected  to be realised, either  by elimination in tax on future earnings or by set off against deferred tax liabilities.Cash and cash equivalentsCash and cash equivalents comprise cash in banks.EquityDividendsDividend distribution proposed by Management for the year is disclosed as a separate equity item.ProvisionsProvisions is booked when the company has a legal or de facto obligation due to an incident occurring before or at the balance sheet date, and it is probable that capital must be ceded in order to meet the obligation.LiabilitiesPayables to credit institutions are recognized at cost at the date of borrowing, equivalent to proceeds received less transaction cost paid.Trade payables and payables to group entities are recognized at cost.Subsequently these financial liabilities are measured at cost.Other liabilities are measured at net realization value.2    Staff costs2022 2021DKK'000Wages and Salaries   51,840    52,058 Pensions   4,014    4,048 Other social security costs   266    328   56,120    56,434 </fsa:DisclosureOfAccountingPolicies>
   <fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod contextRef="ctx-1" id="pp-value-41-1">true</fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod>
   <fsa:ExplanationOfNotDisclosingCashFlowsStatements contextRef="ctx-1" id="pp-value-44-1" xml:lang="en">Omission of cash flow statementPursuant  to  section  86(4)  of  the  Danish  Financial  Statements  Act,  no  cash  flow  statement  has  been prepared. The Company's cash flows are included in the cash flow statement in the consolidated financial statements of UCB S.A.</fsa:ExplanationOfNotDisclosingCashFlowsStatements>
   <fsa:AverageNumberOfEmployees contextRef="ctx-1" decimals="0" unitRef="pure">40</fsa:AverageNumberOfEmployees>
   <fsa:AverageNumberOfEmployees contextRef="ctx-4" decimals="0" unitRef="pure">40</fsa:AverageNumberOfEmployees>
   <fsa:InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes contextRef="ctx-1" id="pp-value-48-1" xml:lang="en">According  to  section  98  B(3)  of  the  Danish  Financial  Statements  Act,  remuneration  to  the  Executive Board has not been disclosed.</fsa:InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes>
   <fsa:DisclosureOfOtherFinanceIncome contextRef="ctx-1" id="pp-value-49-1" xml:lang="en">  Financial incomeDKK'000 2022 2021Interest received from group entities 20 15Other financial income 32 —Exchange gains 61 54113 69</fsa:DisclosureOfOtherFinanceIncome>
   <fsa:DisclosureOfOtherFinanceExpenses contextRef="ctx-1" id="pp-value-50-1" xml:lang="en">   Financial expenses2022 2021Interest paid to group entities   168    218 Other financial expenses   83    50 Exchange losses   67    16   318    284 </fsa:DisclosureOfOtherFinanceExpenses>
   <fsa:DisclosureOfTaxExpenses contextRef="ctx-1" id="pp-value-51-1" xml:lang="en"> Tax on profit for the year2022 2021Current tax for the year   994    1,910 Deferred tax for the year   185    (1,108) Adjustment of tax concerning previous years   (55)    —   1,124    802 </fsa:DisclosureOfTaxExpenses>
   <fsa:ProposedDividendRecognisedInEquity contextRef="ctx-3" decimals="-3" unitRef="dkk">2900000</fsa:ProposedDividendRecognisedInEquity>
   <fsa:ProposedDividendRecognisedInEquity contextRef="ctx-5" decimals="-3" unitRef="dkk">3000000</fsa:ProposedDividendRecognisedInEquity>
   <fsa:TransferredToFromRetainedEarnings contextRef="ctx-1" decimals="-3" unitRef="dkk">1104000</fsa:TransferredToFromRetainedEarnings>
   <fsa:TransferredToFromRetainedEarnings contextRef="ctx-4" decimals="-3" unitRef="dkk">16000</fsa:TransferredToFromRetainedEarnings>
   <fsa:ProfitLoss contextRef="ctx-1" decimals="-3" unitRef="dkk">4004000</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-4" decimals="-3" unitRef="dkk">3016000</fsa:ProfitLoss>
   <fsa:DisclosureOfPropertyPlantAndEquipment contextRef="ctx-1" id="pp-value-52-1" xml:lang="en"> Property, plant and equipmentLeasehold DKK'000improvements &amp; equipmentCost at 1 January 2022   302 Cost at 31 December 2022   302 Depreciation and impairment losses at 1 January 2022   (253) Depreciation and impairment losses at Depreciation for the year   (46) Depreciation and impairment losses at 31 December 2022   (299) Carrying amount at 31 December 2022   3 </fsa:DisclosureOfPropertyPlantAndEquipment>
   <fsa:InformationOnOtherReceivables contextRef="ctx-1" id="pp-value-53-1" xml:lang="en">  Other receivablesOther DKK'000receivablesCost at 1 January 2022 463Additions 776Disposals   (711) Cost at 31 December 2022 528Carrying amount at 31 December 2022 528</fsa:InformationOnOtherReceivables>
   <fsa:ExplanationOfPrepayments contextRef="ctx-1" id="pp-value-54-1" xml:lang="en">  PrepaymentsPrepayments comprise prepaid expenses concerning subsequent financial years.DKK'0002022 2021  169    169 </fsa:ExplanationOfPrepayments>
   <fsa:DisclosureOfProvisionsForDeferredTax contextRef="ctx-1" id="pp-value-55-1" xml:lang="en"> Deferred tax asset2022 2021DKK'000Deferred tax at 1 January 2022   1,286    178 Deferred tax adjustment for the year in the income statement  (186)   1,108     1,100    1,286 Provisions for deferred tax relate to:Property, plant and equipment   50    11 Stock Options   1,050    1,275   1,100    1,286 </fsa:DisclosureOfProvisionsForDeferredTax>
   <fsa:DisclosureOfEquity contextRef="ctx-1" id="pp-value-56-1" xml:lang="en"> EquityThe contributed capital consists of 850,000 shares of a nominal value of DKK 1 each.No shares carry any special rights.</fsa:DisclosureOfEquity>
   <fsa:DisclosureOfOtherProvisions contextRef="ctx-1" id="pp-value-57-1" xml:lang="en">  Provisions for the share option planBased  on  the  performance  of  the  employee  during  the  reference  year  and  on  his/her  job  level,  UCB grants stock awards and stock options on April 1st in the year following the performance year.Stock awards are a promise to deliver a number of shares on the third anniversary of grant on condition that the person remains employed up to and including on the vesting date. The stock awards are granted by UCB S.A The stock awards are share based : UCB SA buys the shares on the market, delivers them to the employee and recharges the cost to the affiliate.A  Stock  Option  gives  you  the  right  to  buy  a  UCB  share  at  a  certain  price  (exercise  price)  during  the exercise period. Upon exercise of the stock options, UCB SA delivers the shares to the employee. In the year of grant, UCB SA recharges the cost of the grant to the affiliate.</fsa:DisclosureOfOtherProvisions>
   <fsa:DisclosureOfContingentLiabilities contextRef="ctx-1" id="pp-value-58-1" xml:lang="en">   Contingent assets, liabilities and other financial obligationsThe Company has leases regarding company cars, printers and furniture, and has committed to give at least six months' notice on the office rental.At  31  December  2022,  the  Company  has  total  contingent  liabilities  within  one  year  of  DKK  1,675 thousand and after one year of 893 DKK thousand. In the prior year, the Company had total contingent liabilities within one year of DKK 2,126 thousand and after one year of DKK 1,381 thousand.</fsa:DisclosureOfContingentLiabilities>
   <fsa:DisclosureOfRelatedParties contextRef="ctx-1" id="pp-value-59-1" xml:lang="en">  Related pary disclosuresRelated party transactionsIn  accordance  with  section  98  c(7)  of  the  Danish  Financial  Statements  Act,  the  Company  has  not disclosed any related party transactions as they were conducted on an arm's length basis.Controlling interestUCB Pharma SA, Allée de la Recherche 60, 1070 Brussels, Belgium.Consolidated financial statementsThe Company is included in the Group Annual Report of UCB S.A.The Group Annual Report of UCB S.A may be obtained at the following address:Allée de la Recherche 60, 1070 Brussels,Belgium </fsa:DisclosureOfRelatedParties>
   <gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1" xml:lang="en">Annual report</gsd:InformationOnTypeOfSubmittedReport>
   <cmn:TypeOfAuditorAssistance contextRef="ctx-1" xml:lang="en">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
   <gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx-1" xml:lang="en">ParsePort XBRL Converter</gsd:ToolForPreparingTheXBRLInstanceDocument>
   <gsd:ReportingPeriodStartDate contextRef="ctx-1" xml:lang="en">2022-01-01</gsd:ReportingPeriodStartDate>
   <gsd:ReportingPeriodEndDate contextRef="ctx-1" xml:lang="en">2022-12-31</gsd:ReportingPeriodEndDate>
   <gsd:PrecedingReportingPeriodStartDate contextRef="ctx-1" xml:lang="en">2021-01-01</gsd:PrecedingReportingPeriodStartDate>
   <gsd:PredingReportingPeriodEndDate contextRef="ctx-1" xml:lang="en">2021-12-31</gsd:PredingReportingPeriodEndDate>
   <fsa:ClassOfReportingEntity contextRef="ctx-1" xml:lang="en">Reporting class C, medium-size enterprise</fsa:ClassOfReportingEntity>
   <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-2" xml:lang="en">Mari-Ann Retz</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
   <gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">33963556</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
   <gsd:NameOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">Deloitte Belastingconsulenten BV</gsd:NameOfSubmittingEnterprise>
   <gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" xml:lang="en">Weidekampsgade 6</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
   <gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" xml:lang="en">2300 København S</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
   <arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
   <arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
</xbrli:xbrl>
